First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis. - Archive ouverte HAL Access content directly
Journal Articles Anticancer Research Year : 2012

First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.

(1, 2) , (3) , (1) , (3) , (3) , (3) , (1) , (1) , (2, 3) , (1, 2)
1
2
3

Abstract

AIM: To carry out a cost minimisation analysis including a comparison of the costs arising from first-line treatment by bevacizumab plus docetaxel (BD) versus bevacizumab plus paclitaxel (BP) of patients with metastatic breast cancer (mBC). Patient and Methods: All consecutive patients with human epidermal growth receptor 2-negative mBC and treated at Besançon University hospital between 2006 and 2010 by a first-line therapy containing bevacizumab plus taxane were retrospectively studied. Economic analysis took into account costs related to drugs, hospitalization and healthcare travel. RESULTS: Progression-free survival difference between the two treatments was insignificant (p-value=0.31). BP treatment was associated with a higher mean total cost than that of BD treatment, €53,093 ± 34,395 versus €60,196 ± 48,766, respectively. CONCLUSION: Whereas bevacizumab is recommended for first-line treatment of mBC with paclitaxel-based chemotherapy, our study has shown that BD treatment is the most cost-efficient regimen. It could be an attractive option in France, with a potential cost saving of €24,000,000 per year.
Not file

Dates and versions

inserm-00842410 , version 1 (08-07-2013)

Identifiers

  • HAL Id : inserm-00842410 , version 1
  • PUBMED : 22843944

Cite

Virginie Nerich, Fernando Bazan, Fanny Compagnat, Erion Dobi, Cristian Villanueva, et al.. First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.. Anticancer Research, 2012, 32 (8), pp.3547-52. ⟨inserm-00842410⟩

Collections

INSERM UNIV-FCOMTE
159 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More